AIR340B Coalition Applauds Congress for Introducing 340B Pause Act
December 21, 2017
Today, the Alliance for Integrity and Reform of 340B (AIR340B) Coalition released the following statement in response to the introduction of H.R. 4710, the “340B Protecting Access for the Underserved and Safety- Net Entities Act”:
AIR340B Coalition Releases New Report on DSH Hospitals’ Declining Charity Care Rates
October 10, 2017
Today, the AIR340B Coalition released a report, which found evidence that disproportionate share hospitals (DSH) participating in the 340B drug discount program often are not using the program as originally intended. The report comes a day before the House Energy & Commerce Subcommittee on Oversight and Investigations holds a hearing to investigate how providers utilize revenue generated by the 340B drug discount program.
In Case You Missed It: New Report Finds Cancer Treatment in Hospitals More Expensive Than in Community Practice Settings
October 2, 2017
The Community Oncology Alliance (COA) released a report last week on the costs of cancer treatment depending on the site of care. The report found that across various types of cancer profiles, the cost of cancer care for patients treated in the community clinic setting is about $8,000 less expensive per month than treatment in the hospital-based setting.* Looked at another way, the total cost of care for cancer patients receiving chemotherapy delivered in the hospital outpatient setting is nearly 60 percent, or $90,144, per year more expensive than the same treatment delivered in independent, community oncology practices.
In Case You Missed It: Washington Hospitals Falling Short on Charity Care, Potentially Discriminating Against Latino Patients
September 19, 2017
The Seattle Times recently wrote on a report conducted by Columbia Legal Services (CLS) that found a record number of hospitals are withholding charity care throughout the state of Washington. 27 of the hospitals referenced are 340B Drug Discount Program covered entities, a program which was designed to help certain health care safety-net providers that serve uninsured or otherwise vulnerable patients reduce outpatient prescription drug costs, giving entities the ability to increase uncompensated and charity care in their local communities.
AIR340B Statement on Energy & Commerce Committee’s Continued Probe into the 340B Program
September 12, 2017
The Alliance for Integrity and Reform of 340B (AIR340B) applauds House Energy and Commerce Committee Chairman Greg Walden (R-OR) and Oversight and Investigations Subcommittee Chairman Tim Murphy (R-PA) for continuing their probe into the 340B drug discount program. Last Friday, the committee leaders sent letters to a variety of covered entities participating in the 340B drug discount program, inquiring about how these institutions calculate program savings and use them to help serve patients in their communities. AIR340B issued the following statement:
ICYMI: Congress Calls For Increased Oversight and Transparency of 340B Program
July 24, 2017
The House Energy & Commerce Subcommittee on Oversight and Investigations held a hearing last Tuesday to examine the Health Resources and Services Administration’s (HRSA) oversight of the 340B drug pricing program.
AIR340B Gains Four New Members
July 19, 2017
The Alliance for Integrity and Reform of 340B (AIR340B) announced the addition of four new members to the coalition: Citizens Against Government Waste (GAGW), Genentech, Medical Oncology Association of Southern California Inc. (MOASC), and the National Medical Association (NMA). These organizations join the diverse group of health care stakeholders that have come together to advance reforms that strengthen and sustain 340B.
New Study Finds Unprecedented 340B Program Growth To Continue
December 6, 2016
A new study released today by the Alliance for Integrity and Reform of 340B (AIR 340B) projects the 340B Drug Pricing Program will continue to expand at an unprecedented rate through 2021, by which time it is expected to exceed $23 billion in total purchases at the 340B price. This rapid expansion would see 340B purchases surpass current Medicare Part B drug reimbursement purchases over the next five years.
Report: Increasing Number of 340B Hospitals Provide Minimal Charity Care
May 12, 2016
The Alliance for Integrity and Reform of 340B (AIR340B) today released a report using public data analyzed by Avalere Health that found a dramatic decline in charity care provided by 340B hospitals in 2014—the first year of the Affordable Care Act’s coverage expansion. Specifically, more than one-third (37 percent) of 340B hospitals provided charity care representing less than 1 percent of total patient costs in 2014. This is notably higher than the 24 percent of hospitals with that low level of charity care in 2011.
Report Finds 340B Hospitals Have Low Compliance with ACA Charity Care Requirements
April 25, 2016
The Alliance for Integrity and Reform of 340B (AIR340B) today released a report from the Berkeley Research Group (BRG) examining hospitals’ compliance with the Affordable Care Act’s (ACA) charity care requirements. The report, which expands on a study published in the New England Journal of Medicine (NEJM) last year, found large numbers of both 340B and non-340B hospitals not complying with key ACA protections for low-income patients.
Fact Sheet Compares, Examines Distribution of Physician Administered Drugs Among 340B and Non-340B Hospitals
February 2, 2016
A fact sheet released today by the Alliance for Integrity and Reform of 340B (AIR340B) uses research from the Berkeley Research Group (BRG) on Medicare Part B hospital outpatient reimbursements. The research found 340B hospitals account for the majority of Part B reimbursement compared to non-340B hospitals and 340B hospitals have been driving most of the growth in Part B reimbursement over time.
340B Hospitals Are More Likely to Acquire Physician Practices, Study Suggests
June 8, 2015
An analysis released today by Avalere Health and funded by the Alliance for Integrity and Reform of 340B (AIR 340B) found hospitals participating in the 340B Drug Pricing Program were more likely to acquire independent physician practices than non-340B hospitals.